GEM
AXSM icon

Global Endowment Management’s Axsome Therapeutics AXSM Stock Holding History

Global Endowment Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,020
Closed -$1.24M – 105
2020
Q1 		$1.24M Buy
+21,020
New +$1.71M 0.11% 43

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Global Endowment Management's AXSM Position: Q2 2020 in Review

Global Endowment Management sold out of Axsome Therapeutics (AXSM) in Q2 2020, closing a stake of 21,020 shares — an estimated $1.24M sold.

Global Endowment Management first reported a position in AXSM in Q1 2020 and held it in 1 quarter. The position peaked at $1.24M in Q1 2020. 190 funds tracked by Wall St. Rank hold AXSM as of Q2 2020.

  • Global Endowment Management reported no remaining Axsome Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Global Endowment Management sold 21,020 Axsome Therapeutics shares in Q2 2020, an estimated $1.24M.
  • Global Endowment Management first reported a position in Axsome Therapeutics in Q1 2020 and held it in 1 quarter.
  • Global Endowment Management's Axsome Therapeutics position peaked at $1.24M in Q1 2020.
  • 190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2020.

Based on Global Endowment Management's 13F filing for Q2 2020, filed 13 Aug 2020.